Ovarian Cancer
📧 Sign up to get email alerts when something new happens for Ovarian Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-08-24Clinical Trial Update: S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer [Phase 2]
Phase 2 SWOG trial evaluating the combination of chemotherapy and surgery for stage III or IV ovarian cancer; results were posted after comp…
-
CLINICAL_TRIALS trial_result · 2012-08-23Clinical Trial Update: TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary [Phase 2]
Phase 2 trial TEACO tested a combination of Taxotere (docetaxel), Eloxatin (oxaliplatin), and Avastin (bevacizumab) in ovarian cancer. The s…
-
CLINICAL_TRIALS trial_result · 2012-08-23Clinical Trial Update: A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer [Phase 2]
Phase 2, single-arm study of volociximab monotherapy in platinum-resistant advanced epithelial ovarian cancer and primary peritoneal cancer …
-
CLINICAL_TRIALS trial_result · 2012-08-14Clinical Trial Update: Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer
The trial evaluated first-line chemotherapy with docetaxel and carboplatin in ovarian cancer (including early-stage and advanced/metastatic …
-
CLINICAL_TRIALS trial_result · 2012-08-13Clinical Trial Update: Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer [Phase 2]
A Phase 2 trial evaluating docetaxel in women with ovarian epithelial cancer or primary peritoneal cancer has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-08-09Clinical Trial Update: Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing [NA]
This clinical trial update documents that a study evaluating counseling interventions for BRCA1/2 cancer susceptibility testing has complete…
-
CLINICAL_TRIALS trial_result · 2012-08-02Clinical Trial Update: PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer [Phase 1]
Phase 1 trial evaluating PS-341 (bortezomib) in combination with carboplatin for platinum- and taxane-resistant recurrent ovarian cancer, pr…
-
CLINICAL_TRIALS trial_result · 2012-08-02Clinical Trial Update: PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer [Phase 1, Phase 2]
A terminated Phase 1/2 trial evaluating PEG-interferon alfa-2b in platinum-resistant ovarian, fallopian tube, and peritoneal cancer.
-
CLINICAL_TRIALS trial_result · 2012-07-13Clinical Trial Update: Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer [Phase 2]
Phase 2 clinical trial update investigating allelic imbalance of BRCA gene expression in individuals at hereditary risk for breast and/or ov…
-
CLINICAL_TRIALS trial_result · 2012-07-11Clinical Trial Update: Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy [Phase 2]
Phase 2 safety and efficacy study of catumaxomab for ovarian cancer after a complete response to chemotherapy has completed, with results po…
-
CLINICAL_TRIALS trial_result · 2012-07-02Clinical Trial Update: Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer [Phase 2]
A Phase 2 clinical trial evaluates docetaxel for recurrent or refractory germ cell cancers, including extragonadal germ cell tumors, ovarian…
-
CLINICAL_TRIALS trial_result · 2012-06-29Clinical Trial Update: Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer [Phase 2]
A Phase 2 trial evaluating adding lonafarnib to standard Paclitaxel/Carboplatin for first-line treatment of epithelial ovarian cancer has be…
-
CLINICAL_TRIALS trial_result · 2012-06-26Clinical Trial Update: Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
This Phase 2 trial evaluated vandetanib for ovarian, fallopian tube, and primary peritoneal cancers; the study was terminated and results we…
-
CLINICAL_TRIALS trial_result · 2012-06-12Clinical Trial Update: Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer [Phase 1]
Phase 1 trial evaluating the maximum tolerated dose and safety, with early efficacy signals, of Genexol®-PM plus carboplatin in advanced ova…
-
CLINICAL_TRIALS trial_result · 2012-06-11Clinical Trial Update: Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer [Phase 2]
A Phase 2 trial evaluating a rebeccamycin analogue in patients with refractory stage III/IV ovarian epithelial cancer has been terminated. T…
-
CLINICAL_TRIALS trial_result · 2012-06-07Clinical Trial Update: Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer [Phase 2]
Phase 2 study of arzoxifene hydrochloride in women with metastatic refractory ovarian cancer or primary peritoneal cancer; the trial has com…
-
CLINICAL_TRIALS trial_result · 2012-06-06Clinical Trial Update: Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy [Phase 3]
This update reports on a Phase 3 trial of amifostine in patients with ovarian epithelial cancer undergoing chemotherapy; the trial status is…
-
CLINICAL_TRIALS trial_result · 2012-06-06Clinical Trial Update: Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery [Phase 2]
Phase 2 trial evaluating octreotide as palliation for cancer-related bowel obstruction that cannot be removed by surgery; the study has comp…
-
CLINICAL_TRIALS trial_result · 2012-06-06Clinical Trial Update: Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine [NA]
A completed clinical trial investigating complementary and alternative medicine approaches in ovarian, peritoneal primary, and fallopian tub…
-
CLINICAL_TRIALS trial_result · 2012-06-06Clinical Trial Update: ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer [Phase 2]
The document reports a Phase 2 trial evaluating ZD4054 (Zibotentan) or placebo plus chemotherapy in patients with advanced ovarian cancer. T…
-
CLINICAL_TRIALS trial_result · 2012-05-31Clinical Trial Update: Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer [Phase 1, Phase 2]
This trial update reports the completion of a Phase 1/2 study evaluating liposomal doxorubicin with carboplatin in gynecologic cancers, incl…
-
CLINICAL_TRIALS trial_result · 2012-05-31Clinical Trial Update: TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer [Phase 3]
A Phase 3 trial evaluating Telcyta (TLK286) in combination with carboplatin versus Doxil in platinum-refractory or resistant ovarian cancer …
-
CLINICAL_TRIALS trial_result · 2012-05-22Clinical Trial Update: Validation of a Laparoscopic Score to Predict the Chance of Optimal Cytoreduction in Advanced Ovarian Cancer Patients [NA]
Completed clinical trial validating a laparoscopic score to predict the chance of achieving optimal cytoreduction in patients with advanced …
-
CLINICAL_TRIALS trial_result · 2012-05-18Clinical Trial Update: Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer [Phase 1, Phase 2]
This completed Phase 1/2 trial evaluated the combination of liposomal doxorubicin (Doxil) and bortezomib in patients with refractory hematol…
-
CLINICAL_TRIALS trial_result · 2012-05-16Clinical Trial Update: Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer [Phase 2]
Phase 2 chemotherapy trial for recurrent, metastatic, or unresectable ovarian, fallopian tube, or primary peritoneal cancer has completed.